Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties

Aksoy S., Abali H., Dincer M., Kilickap S., Gullu I., Tekuzman G.

MEDICAL HYPOTHESES, vol.62, no.6, pp.942-944, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 62 Issue: 6
  • Publication Date: 2004
  • Doi Number: 10.1016/j.mehy.2004.02.001
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.942-944
  • Eskisehir Osmangazi University Affiliated: Yes


Bisphosphonates, effectively used for metastatic bone disease and hypercalcemia, may evidentially have antiangiogenic properties. However, mechanism(s) of antiangiogenic effects of bisphosphonates are not fully understood. Their most pronounced effect is on metabolism of calcium, which is a main point of intersection for many distinct molecular signaling pathways that promote and modulate angiogenesis. An elevation of Ca2+ plays a role in the mitogenic and secretory effects of growth factors. Some preclinical clues imply that antiangiogenic effects of bisphosphonates are related to its well-known hypocalcemic activity. Consequently, it may not be right to routinely recommend vitamin D and calcium supplementation to correct hypocalcemia unless it is symptomatic. (C) 2004 Elsevier Ltd. All rights reserved.